ERJ Open Research (Apr 2025)

Delaying disease progression in COPD with early escalation to triple therapy: a modelling study (DEPICT-2)

  • Dave Singh,
  • Diego Fabian Litewka,
  • Joan B. Soriano,
  • Adrian Rendon,
  • Frederico Leon Arrabal Fernandes,
  • Rafael Páramo-Arroyo,
  • Tim Trinidad,
  • Hakan Günen,
  • Sudeep Acharya,
  • Bhumika Aggarwal,
  • Gur Levy,
  • Chris Compton,
  • Abdelkader El Hasnaoui,
  • Peter Daley-Yates

DOI
https://doi.org/10.1183/23120541.00438-2024
Journal volume & issue
Vol. 11, no. 2

Abstract

Read online

Introduction In patients with COPD, dual bronchodilator (long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA)) and triple therapy (inhaled corticosteroid/LAMA/LABA) reduce the risk of exacerbations and lung function decline in the short–mid-term, but their long-term impact is unknown. This modelling study explores long-term impact of these therapies on lung function decline, quality of life (QoL) and all-cause mortality. Methods This modelling approach used a longitudinal nonparametric superposition model using published data regarding exacerbations, QoL (assessed by St George's Respiratory Questionnaire (SGRQ)) and mortality. The model simulated disease progression from 40 to 75 years of age and assessed the impact of initiating dual bronchodilator at age 45 years (“LAMA/LABA only” group) and escalation to triple therapy at age 50 years (“Escalation to triple” group) on forced expiratory volume in 1 s (FEV1) decline, QoL and mortality. Results Model simulation predicted that by 75 years of age, “LAMA/LABA only” preserves 159.1 mL of FEV1 versus no treatment, while “Escalation to triple” preserves an additional 376.5 mL and 217.3 mL of FEV1 versus no pharmacotherapy and “LAMA/LABA only”, respectively. In “LAMA/LABA only”, the SGRQ score reduces (−3.2) versus no treatment, which further reduces to −7.5 in “Escalation to triple”. In “LAMA/LABA only”, mortality reduces by 5.4% by 75 years versus no treatment, while the “Escalation to triple” shows further decrease in mortality by 12.0%. Conclusion Early pharmacotherapy initiation and escalation from dual bronchodilator to triple therapy could slow disease progression by preserving lung function and improving QoL and survival in patients with COPD.